Key result
Anticoagulant therapy for incidental VTE in cancer patients resulted in a 12.7% rate of recurrent VTE or major bleeding, compared to 13.8% for symptomatic VTE.
Why the study?
Current guidance suggesting similar treatment for incidental and symptomatic VTE in cancer patients was mainly based on retrospective data.
Do clinical outcomes differ between cancer patients with incidental versus symptomatic venous thromboembolism receiving anticoagulant therapy?
Population
331 patients with incidental VTE and 679 patients with symptomatic VTE in cancer
Comparison
Incidental VTE vs symptomatic VTE treated with edoxaban or dalteparin
Design
Subgroup analysis of a randomised controlled trial
Follow-up
12-month study period
Authors
Loading...
Supports similar anticoagulation for incidental and symptomatic cancer-associated VTE; leaves open need for prospective confirmation.
RCT (n=1,010)
randomised
Do clinical outcomes differ between cancer patients with incidental versus symptomatic venous thromboembolism receiving anticoagulant therapy?
Absolute Event Rate: 12.7% vs 13.8%
Incidental VTE in cancer patients carries a substantial risk of adverse outcomes comparable to symptomatic VTE, supporting current guidelines to treat both presentations similarly.
Mulder et al. (2019) conducted an RCT in Cancer-associated venous thromboembolism (n=1,010). Anticoagulant therapy for incidental VTE vs. Anticoagulant therapy for symptomatic VTE was evaluated on Composite of first recurrent VTE or major bleeding. Anticoagulant therapy for incidental VTE in cancer patients resulted in a 12.7% rate of recurrent VTE or major bleeding, compared to 13.8% for symptomatic VTE.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: